NaxitamabNaxitamab
MedChemExpress (MCE)
HY-P99206
1879925-92-4
Naxitamab-gqgk
Humanized 3F8
Hu3F8
98.13%
Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping with dry ice.
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers.
Naxitamab (Hu3F8
72 h) has cytotoxicity against neuroblastoma cell line LAN-1 with an EC50 value of 5.1 μg/mL[1]. Naxitamab (0.1-1 μg/mL
4 h
peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) has antibody-dependent cell-mediated cytotoxic effects (ADCC)[1].
Naxitamab (Hu3F8
100 mg/kg
i.v.
twice a week, for 4 weeks
athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts[1].
Chimeric
Human IgG1 kappa
Human IgG1 kappa, Isotype Control
| | | |
| | | | | |
[1]. Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012 Jul 1
1(4):477-486. [Content Brief]
[2]. Markham A. Naxitamab: First Approval. Drugs. 2021 Feb
81(2):291-296. [Content Brief]